CB8025-21845: A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study To Evaluate The Safety, Tolerability, And Efficacy Of Seladelpar Administered For 24 Weeks In Adult Subjects With Primary Sclerosing Cholangitis
|Effective start/end date||1/29/20 → 7/30/20|
- CYMABAY THERAPEUTICS, INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.